Tumor acidity, chemoresistance and proton pump inhibitors

Future Oncology

Volumn 1, Issue 6, 2005, Pages 779-786

  De Milito, Angelo ^a   Fais, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

acidic vesicles; chemoresistance; cytotoxic drugs; omeprazole; proton pump inhibitors; tumor acidity; vacuolar H+ ATPases

Indexed keywords

ANTINEOPLASTIC AGENT; PROTON PUMP;

ACID BASE BALANCE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG RESISTANCE; EXTRACELLULAR SPACE; HUMAN; PH; REVIEW;

ACID-BASE EQUILIBRIUM; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SPACE; HUMANS; HYDROGEN-ION CONCENTRATION; PROTON PUMPS;

EID: 33847377377     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.779     Document Type: Review

References (71)

1. Raghunand N, Mahoney B, van Sluis R, Baggett B, Gillies RJ: Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 3, 227-235 (2001).
2. Morita T, Nagaki T, Fukuda I, Okumura K: Clastogenicity of low pH to various cultured mammalian cells. Mutat. Res. 268, 297-305 (1992).
3. Martinez-Zaguilan R, Seftor EA, Seftor RE et al.: Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis 14, 176-186 (1996).
4. Warburg O: On the origin of cancer cells. Science 123, 309-314 (1956).
5. Wike-Hooley JL, Haveman J, Reinhold HS: The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 2, 343-366 (1984).
6. Griffiths JR: Are cancer cells acidic? Br. J. Cancer 64, 425-427 (1991).
7. Negendank W: Studies of human tumors by MRS: a review. NMR Biomed. 5, 303-324 (1992).
8. Wahl ML, Owen JA, Burd R et al.: Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol. Cancer Ther. 1, 617-628 (2002).
9. Coss RA, Storck CW, Daskalakis C, Berd D, Wahl ML: Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells. Mol. Cancer Ther. 2, 383-388 (2003).
10. Gillies RJ, Liu Z, Bhujwalla Z: 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am. J. Physiol. 267, C195-C203 (1994).
11. McCoy CL, Parkins CS, Chaplin DJ et al.: The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. Br. J. Cancer 72, 905-911 (1995).
12. Raghunand N, He X, van Sluis R et al.: Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer 80, 1005-1011 (1999).
13. Simon S, Roy D, Schindler M: Intracellular pH and the control of multi-drug resistance. Proc. Natl Acad. Sci. USA 91, 1128-1132 (1994).
14. Mahoney BP, Raghunand N, Baggett B, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 66, 1207-1218 (2003).
15. Luciani F, Spada M, De Milito A et al.: Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl Cancer Inst. 96, 1702-1713 (2004).
16. Svastova E, Hulikova A, Rafajova M et al.: Hypoxia activates the capacity of tumorassociated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577, 439-445 (2004).
17. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
18. Yamagata M, Hasuda K, Stamato T, Tannock IF: The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 77, 1726-1731 (1998).
19. Newell K, Franchi A, Pouyssegur J, Tannock I: Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc. Natl Acad. Sci. USA 90, 1127-1131 (1993).
20. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E: CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J. Biol. Chem. 279, 26991-27007 (2004).
21. Luciani F, Molinari A, Lozupone F et al.: P glycoprotein-actin association through ERM family proteins: a role in Pglycoprotein function in human cells of lymphoid origin. Blood 99, 641-648 (2002).
22. Newell K, Wood P, Stratford I, Tannock I: Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours. Br. J. Cancer 66, 311-317 (1992).
23. Raghunand N, Gillies RJ: pH and drug resistance in tumors. Drug Resist Update 3, 39-47 (2000).
24. Ohtsubo T, Igawa H, Saito T et al.: Acidic environment modifies heat- or radiationinduced apoptosis in human maxillary cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 49, 1391-1398 (2001).
25. Gatenby RA, Vincent TL: An evolutionary model of carcinogenesis. Cancer Res. 63, 6212-6220 (2003).
26. Rotin D, Steele-Norwood D, Grinstein S, Tannock I: Requirement of the Na+/H+ exchanger for tumor growth. Cancer Res. 49, 205-211 (1989).
27. Raghunand N, Gillies RJ: pH and chemotherapy. Novartis Found Symp. 240, 199-211; discussion 265-268 (2001).
28. Raghunand N, Mahoney BP, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem. Pharmacol. 66, 1219-1229 (2003).
29. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H: Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin. Exp. Metastasis 15, 382-392 (1997).
30. Rozhin J, Sameni M, Ziegler G, Sloane BF Pericellular: pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 54, 6517-6525 (1994).
31. Lugini L, Lozupone F, Matarrese P et al.: Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab. Invest. 83, 1555-1567 (2003).
32. Saitoh O, Wang WC, Lotan R, Fukuda M: Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J. Biol. Chem. 267, 5700-5711 (1992).
33. Glunde K, Guggino SE, Solaiyappan M et al.: Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 5, 533-545 (2003).
34. Andreola G, Rivoltini L, Castelli C et al.: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195, 1303-1316 (2002).
35. Taylor DD, Gercel-Taylor C: Tumourderived exosomes and their role in cancerassociated T-cell signalling defects. Br. J. Cancer 92, 305-311 (2005).
36. Huber V, Fais S, Iero M et al.: Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128, 1796-1804 (2005).
37. Dietel M, Arps H, Lage H, Niendorf A: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50, 6100-6106 (1990).
38. Bobichon H, Colin M, Depierreux C, Liautaud-Roger F, Jardillier JC: Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J. Exp. Ther. Oncol. 1, 49-61 (1996).
39. Cleary I, Doherty G, Moran E, Clynes M: The multi-drug resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. 53, 1493-1502 (1997).
40. Bour-Dill C, Gramain MP, Merlin JL, Marchal S, Guillemin F: Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multi-drug resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry 39, 16-25 (2000).
41. Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ: pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem. Pharmacol. 57, 1047-1058 (1999).
42. Schindler M, Grabski S, Hoff E, Simon SM: Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycinresistant cells (MCF-7adr). Biochemistry 35, 2811-2817 (1996).
43. Hurwitz SJ, Terashima M, Mizunuma N, Slapak CA: Vesicular anthracycline accumulation in doxorubicin-selected U- 937 cells: participation of lysosomes. Blood 89, 3745-3754 (1997).
44. Altan N, Chen Y, Schindler M, Simon SM: Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med. 187, 1583-1598 (1998).
45. Larsen AK, Escargueil AE, Skladanowski A: Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 85, 217-229 (2000).
46. Ouar Z, Lacave R, Bens M, Vandewalle A: Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug resistant cells. Cell. Biol. Toxicol. 15, 91-100 (1999).
47. Sun-Wada GH, Wada Y, Futai M: Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. Cell. Struct. Funct. 28, 455-463 (2003).
48. Vaananen HK, Karhukorpi EK, Sundquist K et al.: Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J. Cell. Biol. 111, 1305-1311 (1990).
49. Marquardt D, Center MS: Involvement of vacuolar H(+)-adenosine triphosphatase activity in multi-drug resistance in HL60 cells. J. Natl Cancer Inst. 83, 1098-102 (1991).
50. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ: Vacuolar-type H(+)- ATPases are functionally expressed in plasma membranes of human tumor cells. Am. J. Physiol. 265, C1015-1029 (1993).
51. Murakami T, Shibuya I, Ise T et al.: Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int. J. Cancer 93, 869-874 (2001).
52. Izumi H, Torigoe T, Ishiguchi H et al.: Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev. 29, 541-549 (2003).
53. Ouar Z, Bens M, Vignes C et al.: Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem. J. 370, 185-93 (2003).
54. Larsson H, Mattson H, Sundell G, Carlsson E: Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Scand. J. Gastroenterol. (Suppl.) 108, 23-35 (1985).
55. Wallmark B, Larsson H, Humble L: The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. J. Biol. Chem. 260, 13681-13684 (1985).
56. Wallmark B, Lorentzon P, Larsson H: The mechanism of action of omeprazole-a survey of its inhibitory actions in vitro. Scand. J. Gastroenterol. 108, (Suppl.) 37-51 (1985).
57. Puscas I, Coltau M, Baican M, Domuta G: Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). J. Pharmacol. Exp. Ther. 290, 530-534 (1999).
58. Horn J: The proton-pump inhibitors: similarities and differences. Clin. Ther. 22, 266-280; discussion 265 (2000).
59. Mizunashi K, Furukawa Y, Katano K, Abe K: Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif. Tissue Int. 53, 21-25 (1993).
60. Graber ML, Devine P: Omeprazole and SCH-28080 inhibit acid secretion by the turtle urinary bladder. Ren. Physiol. Biochem. 16, 257-267 (1993).
61. Sabolic I, Brown D, Verbavatz JM, Kleinman J: H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am. J. Physiol. 266, F868-F877 (1994).
62. Wallmark B, Brandstrom A, Larsson H: Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H++K+)-ATPase within the parietal cell. Biochim. Biophys. Acta 778, 549-558 (1984).
63. Biswas K, Bandyopadhyay U, Chattopadhyay I et al.: A novel anti-oxidant and anti-apoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J. Biol. Chem. 278, 10993-11001 (2003).
64. Agastya G, West BC, Callahan JM: Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol. Immunotoxicol. 22, 357-372 (2000).
65. De Milito A, Fais S Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother 6, 1049-1054 (2005).
66. Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49, 4373-4384 (1989).
67. Roos A: Weak acids, weak bases and intracellular pH. Respir. Physiol. 33, 27-30 (1978).
68. Gillies RJ, Deamer DW: Intracellular pH changes during the cell cycle in Tetrahymena. J. Cell. Physiol. 100, 23-31 (1979).
69. Taylor CW, Dalton WS, Parrish PR et al.: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer 63, 923-9 (1991).
70. Cianfriglia M, Cenciarelli C, Tombesi M et al.: Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug resistant variants of CEM cells. Int. J. Cancer 45, 95-103 (1990).
71. Breedveld P, Pluim D, Cipriani G et al.: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65, 2577-2582 (2005).